CoChat
Sign Up
Cited by 29Pharmacogenetics and Drug MetabolismAnalytical Methods in PharmaceuticalsParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat

Li, Ziwei, Zhang, Jun, Zhang, Yufeng, Zuo, Zhong·2019·Journal of Pharmaceutical and Biomedical Analysis
DOI 10.1016/j.jpba.2019.02.004
Open this paper in CoChat — free account

Abstract

Simvastatin is known as a pro-drug, which could be hydrolyzed by esterases to its active form, simvastatin acid. Although pharmacokinetics of simvastatin and simvastatin acid have been widely studied, hydrolysis of simvastatin to simvastatin acid during blood sampling and plasma preparation has been overlooked in the previous studies, leading to underestimation of simvastatin concentration and overestimation of simvastatin acid concentration in plasma. Since both efficacy and adverse drug reaction of simvastatin are highly dependent on simvastatin and simvastatin acid concentrations in vivo, accurate assessment of the two compounds are critical in their pharmacokinetic and pharmacodynamic studies. The current study was proposed aiming to investigate the esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on the pharmacokinetic study of simvastatin and simvastatin acid. Using various esterase inhibitors including potassium florid (KF), bis(4-nitrophenyl) phosphate (BNPP), and ethylenediaminetetraacetic acid (EDTA), carboxylesterase was found to be the major esterase that hydrolyzed simvastatin in rat blood, while carboxylesterase and paraoxonase were the major esterases mediating the hydrolysis of simvastatin in human blood. Further studies using human recombinant enzymes identified simvastatin as substrates of PON1, CES1b, PON3 and CES1c with Cl int of 8.75, 5.77, 3.93, and 2.45 μL/min/mg protein. Therefore, inhibition treatments with 20 mM BNPP and 50 mM KF/ 10 mM EDTA were developed to efficiently prevent the hydrolysis of simvastatin during blood sampling and plasma preparation in rat/human. The subsequent pharmacokinetics of orally administered simvastatin at 8.66 mg/kg in rats found that the C max and AUC 0-∞ of simvastatin in absence of such esterase inhibitors in the blood sampling process were only 17.04 ± 6.60% and 15.30 ± 6.76% of those in presence of the inhibitors, whereas the C max and AUC 0-∞ of simvastatin acid were 1.60 ± 0.30 and 1.80 ± 0.22 times of that obtained in presence of the inhibitors. Nevertheless, T 1/2 of simvastatin and simvastatin acid remained the same regardless of the blood sampling method. Our current study for the first time demonstrated the importance for assessment of simvastatin stability during the blood sampling and plasma preparation process, which may be applicable to therapeutic drug monitoring of not only simvastatin but also other pro-drugs/compounds sharing similar metabolic properties.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jpba.2019.02.004

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 44

  1. Prueksaritanont, 1997, In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450S, Drug Metab. Dispos., 25, 1191
  2. Fukami, 2012, The emerging role of human esterases, Drug Metab. Pharmacok., 27, 466, 10.2133/dmpk.DMPK-12-RV-042 · DOI
  3. Wang, 2015, Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin, Biol. Pharm. Bull., 38, 292, 10.1248/bpb.b14-00679 · DOI
  4. Draganov, 2000, Rabbit serum paraoxonase 3 (PON3) is a high-density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation, J. Biol. Chem., 275, 33435, 10.1074/jbc.M004543200 · DOI
  5. Draganov, 2005, Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities, J. Lipid Res., 46, 1239, 10.1194/jlr.M400511-JLR200 · DOI
  6. Billeclke, 2000, Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters, Drug Metab. Dispos., 28, 1335
  7. Draganov, 2004, Pharmacogenetics of paraoxonases: a brief review, N-S Arch. Pharmacol., 369, 78, 10.1007/s00210-003-0833-1 · DOI
  8. Satoh, 1998, The mammalian carboxylesterases: from molecules to functions, Annu. Rev. Pharmacol. Toxicol., 38, 257, 10.1146/annurev.pharmtox.38.1.257 · DOI
  9. Oda, 2015, A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development, Drug Metab. Pharmacokinet., 30, 30, 10.1016/j.dmpk.2014.12.001 · DOI
  10. Na, 2009, Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma, Proteomics, 9, 3989, 10.1002/pmic.200900105 · DOI
  11. Furihata, 2005, Dexamethasone-induced methylprednisolone hemisuccinate hydrolase: Its identification as a member of the rat carboxylesterase 2 family and its unique existence in plasma, Biochem. Pharmacol., 69, 1287, 10.1016/j.bcp.2005.01.017 · DOI
  12. Pellin, 1990, Distribution and some biochemical properties of rat paraoxonase activity, Neurotoxicol. Teratol., 12, 611, 10.1016/0892-0362(90)90071-J · DOI
  13. McCracken, 1993, Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood, Biochem. Pharmacol., 45, 31, 10.1016/0006-2952(93)90373-5 · DOI
  14. Getz, 2004, Paraoxonase, a cardioprotective enzyme: continuing issues, Curr. Opin. Lipidol., 15, 261, 10.1097/00041433-200406000-00005 · DOI
  15. Rodrigo, 2001, Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role, Chem. Biol. Interact., 137, 123, 10.1016/S0009-2797(01)00225-3 · DOI
  16. Rodrigo, 2003, Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties, Biochem. J., 376, 261, 10.1042/bj20030732 · DOI
  17. Rodrigo, 1997, Purification and characterization of paraoxon hydrolase from rat liver, Biochem. J., 321, 595, 10.1042/bj3210595 · DOI
  18. Mochizuki, 1998, Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence, Gene, 213, 149, 10.1016/S0378-1119(98)00193-0 · DOI
  19. Levy, 2007, Biological role, protein expression, subcellular localization, and oxidative stress response of paraoxonase 2 in the intestine of humans and rats, Am. J. Physiol. Gastr. L., 293, G1252, 10.1152/ajpgi.00369.2007 · DOI
  20. Li, 2005, Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma, Biochem. Pharmacol., 70, 1673, 10.1016/j.bcp.2005.09.002 · DOI
  21. Imai, 2006, Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine, Drug Metab. Dispos., 34, 1734, 10.1124/dmd.106.009381 · DOI
  22. Ricaurte, 2006, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity, Ann. Pharmacother., 40, 753, 10.1345/aph.1G462 · DOI
  23. Gumbrevicius, 2012, Paracetamol and simvastatin: a potential interaction resulting in hepatotoxicity, Medicina, 48, 379, 10.3390/medicina48070056 · DOI
  24. Andreou, 2003, Potential drug interaction between simvastatin and danazol causing rhabdomyolysis, Can. J. Clin. Pharmacol., 10, 172
  25. Cheng, 2002, Rhabdomyolysis due to probable interaction between simvastatin and ritonavir, Am. J. Health. Syst. Pharm., 59, 728, 10.1093/ajhp/59.8.728 · DOI
  26. Wilke, 2012, The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy, Clin. Pharmacol. Ther., 92, 112, 10.1038/clpt.2012.57 · DOI
  27. Wang, 2000, Second-derivative UV spectrometric determination of simvastatin in its tablet dosage form, J. Pharm. Biomed. Anal., 21, 1243, 10.1016/S0731-7085(99)00231-9 · DOI
  28. Ochiai, 1997, Determination of simvastatin and its active metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection after derivatization with 1-bromoacetylpyrene, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 694, 211, 10.1016/S0378-4347(97)00091-1 · DOI
  29. Takano, 1990, A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative, Biomed. Environ. Mass Spectrom., 19, 577, 10.1002/bms.1200190910 · DOI
  30. Alvarez-Lueje, 2005, Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography, J. AOAC Int., 88, 1631, 10.1093/jaoac/88.6.1631 · DOI
  31. Piecha, 2009, Stability studies of cholesterol lowering statin drugs in aqueous samples using HPLC and LC-MS, Environ. Chem. Lett., 8, 185, 10.1007/s10311-009-0207-0 · DOI
  32. Bews, 2014, Simultaneous quantification of simvastatin and simvastatin hydroxy acid in blood serum at physiological pH by ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC/MS/MS), J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 947, 145, 10.1016/j.jchromb.2013.12.030 · DOI
  33. Barrett, 2006, Validated HPLC-MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma, J. Pharm. Biomed. Anal., 41, 517, 10.1016/j.jpba.2005.11.020 · DOI
  34. Shanmugam, 2011, Evaluation of pharmacokinetics of simvastatin and its pharmacologically active metabolite from controlled-release tablets of simvastatin in rodent and canine animal models, Biomol. Ther. (Seoul), 19, 248, 10.4062/biomolther.2011.19.2.248 · DOI
  35. Zhu, 2013, Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation, J. Pharmacol. Exp. Ther., 344, 665, 10.1124/jpet.112.201640 · DOI
  36. Tang, 2006, Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol, J. Pharmacol. Exp. Ther., 319, 1467, 10.1124/jpet.106.110577 · DOI
  37. Aharoni, 2004, Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization, P. Natl. Acad. Sci. U.S.A., 101, 482, 10.1073/pnas.2536901100 · DOI
  38. Heymann, 1969, Inhibition of phenacetin- and acetanilide-induced methemoglobinemia in rat by carboxylesterase inhibitor bis-[p-nitrophenyl] phosphate, Biochem. Pharmacol., 18, 801, 10.1016/0006-2952(69)90050-1 · DOI
  39. Vickers, 1990, Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug, Drug Metab. Dispo., 18, 138
  40. Suchocka, 2006, RP-HPLC determination of paraoxonase 3 activity in human blood serum, J. Pharm. Biomed. Anal., 42, 113, 10.1016/j.jpba.2006.02.015 · DOI
  41. Précourt, 2011, The three-gene paraoxonase family: physiologic roles, actions and regulation, Atherosclerosis, 214, 20, 10.1016/j.atherosclerosis.2010.08.076 · DOI
  42. Arenas, 2017, Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients, PLoS One, 12, 10.1371/journal.pone.0188633 · DOI
  43. Hosokawa, 1995, Interindividual variation in carboxylesterase levels in human liver microsomes, Drug Metab. Dispos., 23, 1022
  44. Rainwater, 2009, Determinants of variation in human serum paraoxonase activity, Heredity, 102, 147, 10.1038/hdy.2008.110 · DOI

Cited by

Sorted by citations

Metadata

Authors
Li, Z., Zhang, J., Zhang, Y., & Zuo, Z.
Affiliations
Chinese University of Hong Kong (HK)
Corresponding author
Zuo, Zhong
ORCID
Venue
Journal of Pharmaceutical and Biomedical Analysis
Publisher
Elsevier BV
Published
2019-05
Volume
168
Pages
13-22
ISSN
0731-7085 (ISSN-L)
DOI
10.1016/j.jpba.2019.02.004
OpenAlex
W2912272555
Cited by
29
References
1
Citations by year
2026: 3 · 2025: 6 · 2024: 5 · 2023: 1 · 2022: 9 · 2021: 2 · 2020: 3
FWCI
3.55
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Pharmaceutical and Biomedical Analysis (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
simvastatin acid, prodrug activation, carboxylesterase, paraoxonase, esterase inhibitors, plasma preparation, pharmacokinetics, statins, HMG-CoA reductase inhibition
MeSH terms
Administration, Oral, Animals, Enzyme Inhibitors, Esterases, Humans, Hydrolysis, Male, Prodrugs, Species Specificity, Drug Monitoring, Rats, Sprague-Dawley, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Area Under Curve, Simvastatin, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review